Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer

DESTINY-Breast04 to evaluate [fam-] trastuzumab deruxtecan (DS-8201) versus investigator's choice in HER2 low, unresectable and/or metastatic breast cancer previously treated with standard chemotherapy No anti-HER2 therapies are currently approved for H... Biopharmaceuticals, Oncology Daiichi Sankyo, trastuzumab, breast cancer, HER2
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news